| dc.contributor.author | Tennikova, Tatiana | |
| dc.contributor.author | Urtti, Arto | |
| dc.date.accessioned | 2019-09-26T09:45:19Z | |
| dc.date.available | 2019-09-26T09:45:19Z | |
| dc.date.issued | 2019 | |
| dc.identifier.uri | https://erepo.uef.fi/handle/123456789/7777 | |
| dc.description.abstract | Drug delivery to ocular targets is problematic, especially in retinal disease treatment. Therefore, targeted drug delivery, prolonged drug action, and minimally invasive treatments are needed. In this review, we describe cell technologies for drug delivery. These technologies are based on genetic engineering and nongenetic-based approaches for cell modification. In principle, cell technologies enable targeted delivery, long drug action, and minimally invasive administration, but they have only been sparsely studied for ocular drug delivery. Herein, these technologies are discussed in the ocular context. | |
| dc.language.iso | englanti | |
| dc.publisher | © Elsevier BV | |
| dc.relation.ispartofseries | Drug discovery today | |
| dc.relation.uri | http://dx.doi.org/10.1016/j.drudis.2018.12.004 | |
| dc.rights | CC BY-NC-ND 4.0 | |
| dc.title | Modified cells as potential ocular drug delivery systems | |
| dc.description.version | final draft | |
| dc.contributor.department | School of Pharmacy, Activities | |
| uef.solecris.id | 59286028 | en |
| dc.type.publication | Tieteelliset aikakauslehtiartikkelit | |
| dc.relation.doi | 10.1016/j.drudis.2018.12.004 | |
| dc.description.reviewstatus | peerReviewed | |
| dc.format.pagerange | 1621-1626 | |
| dc.relation.issn | 1359-6446 | |
| dc.relation.issue | 8 | |
| dc.relation.volume | 24 | |
| dc.rights.accesslevel | openAccess | |
| dc.type.okm | A2 | |
| uef.solecris.openaccess | Ei | |
| dc.rights.copyright | © 2019 Elsevier Ltd | |
| dc.type.displayType | Artikkeli | fi |
| dc.type.displayType | Article | en |
| uef.rt.id | 9019 | en |
| dc.rights.url | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
